Novo Nordisk A/S (NVO)
| Market Cap | 563.06B |
| Revenue (ttm) | 35.35B |
| Net Income (ttm) | 12.92B |
| Shares Out | 4.38B |
| EPS (ttm) | 2.87 |
| PE Ratio | 44.83 |
| Forward PE | 37.59 |
| Dividend | $0.98 (0.76%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 2,893,776 |
| Open | 129.09 |
| Previous Close | 128.66 |
| Day's Range | 128.33 - 130.27 |
| 52-Week Range | 75.56 - 138.28 |
| Beta | 0.20 |
| Analysts | Strong Buy |
| Price Target | 133.00 (+3.57%) |
| Earnings Date | May 2, 2024 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $133.0, which is an increase of 3.57% from the latest price.
News
Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies
Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons i...
Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.
Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new s...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The...
Gates Foundation joins Novo Nordisk, Wellcome on $300M global health effort
The Bill & Melinda Gates Foundation is committing $100 million to a new joint partnership that will support innovation and research that address global health challenges.
Gates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And Nutrition
The Bill & Melinda Gates Foundation, Wellcome Trust and Novo Nordisk Foundation joined forces on Monday to tackle some of the world's most pressing health problems, an endeavor that pulls together thr...
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
US FTC seeks more information on Novo Nordisk parent-Catalent deal
The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReS...
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its e...
Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut
Novo Nordisk said it will cut prices of Wegovy amid rising sales and competition. Sales of the blockbuster drug more than doubled in the first quarter year-on-year.
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the company
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk pulling back despite strong quarter.
25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway
Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers f...
Novo Nordisk CEO talks soaring weight-loss drug demand, Q1 earnings
Danish pharmaceutical company Novo Nordisk (NVO) topped first-quarter profit expectations, bringing in $9.5 billion in revenue over Wall Street estimates of $9.2 billion. However, the company fell sho...
Novo Nordisk faces competitive market: Novasecta
Subscribe to CNBC International TV: http://cnb.cx/2wAkfMv Subscribe to CNBC International: http://cnb.cx/2gft82z LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www.tik...
Novo Nordisk showed 'extraordinary growth' but faces competitive market: Novasecta
John Rountree, managing partner at Novasecta, comments on Danish pharma giant Novo Nordisk's first-quarter earnings.
Novo Nordisk CEO on Wegovy, Ozempic Supplies and Pricing
Novo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples with supply constraints and competition from Eli Lilly. CEO Lars Fruergaard Jor...
Novo Nordisk beats expectations but fails to impress some traders with new guidance
CNBC's Silvia Amaro reports on the latest Novo Nordisk results.
Novo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs
Novo Nordisk (NVO) reported first-quarter earnings Thursday that beat analysts' estimates as demand surged for its weight loss drugs, Ozempic and Wegovy.
Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1
Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said on ...
Novo Won't Meet Wegovy Demand in Short-Medium Term: CFO
“Given the significant global demand, it's not in the short or medium term that we're going to meet full global demand,” Chief Financial Officer Karsten Munk Knudsen said in an interview. -------- Mor...